China Biopharmaceutical (01177): 52 research results will be announced at the 2024 ASCO Annual Meeting
Zhitong Finance App News, China Biopharmaceutical (01177) announced that the Group's Class 1 innovative drugs “anlotinib (small molecule multi-target receptor tyrosine kinase inhibitor)”, “abergastine α (third-generation long-acting G-CSF)”, “piamprizumab (anti-PD-1)” and “FS222 (PD-L1/CD137 double antibody)”, “bemosubimab (anti-PDL1)”, “TQB3617 (BET inhibitor)”, “TQB3728” IAP antagonists), “TQB2930 ( HER2 dual antibody)” will wait until 20
中國生物製藥:二零二三年年報
Sino Biopharm Completes Phase I Study of Hepatitis B Drug
Sino Biopharmaceutical (HKG:1177) said it recently successfully completed the phase I clinical study of its self-developed drug TQA3038 (siRNA), according to a Thursday filing with the Hong Kong Excha
China Biopharmaceutical (01177.HK): Class 1 innovative drug “TQA3038 (siRNA)” completed phase I clinical research
Gelonghui, April 25 | China Biopharmaceutical (01177.HK) announced that the Group's self-developed Class 1 innovative drug “TQA3038 (siRNA)” has recently successfully completed phase I clinical research. TQA3038 injection is a small interfering RNA (siRNA) drug independently developed by the Group to target hepatitis B virus (HBV). The indication is chronic hepatitis B. As an N-acetylgalactosamine (GalNAc) -conjugated siRNA drug, TQA3038 can be concentrated in the liver to effectively degrade targeted RNA and inhibit translation of related proteins, thus
Zhitong Hong Kong Shareholders' Rights Disclosure | April 24
Disclosure of Hong Kong Stock Shareholders' Rights | April 24
China Biopharmaceuticals (01177.HK) received 2 million additional shares from Chairman Xie Qirun
Gelonghui, April 24 | According to the latest equity disclosure data of the Stock Exchange, on April 23, 2024, China Biopharmaceutical (01177.HK) was granted an increase of 2 million shares at an average price of HK$2.5891 per share on the market, involving approximately HK$5.1782 million. After the increase in holdings, Xie Qirun's latest shareholding was 6 million shares, and the shareholding ratio increased from 0.02% to 0.03%.
China Biopharmaceuticals (01177.HK) gains 5 million shares by Executive Director Xie Chengrun
Gelonghui, April 23 | According to the latest equity disclosure data of the Stock Exchange, on April 19, 2024, China Biopharmaceutical (01177.HK) was granted an increase of 5 million shares by Executive Director Xie Chengrun on the market at an average price of HK$239 per share, involving approximately HK$116.19,500. After the increase in holdings, Tse Chengyun's latest shareholding was 4,055,000,000 shares, and the shareholding ratio increased from 21.54% to 21.57%.
Changes in Hong Kong stocks | Zhongsheng Pharmaceuticals (01177) is now up more than 5%, key registration studies on the innovative drug lovaxitinib tablets have reached the main end
Zhongsheng Pharmaceutical (01177) is now up more than 5%. As of press release, it has risen 4.7% to HK$2.45, with a turnover of HK$27.146,500.
Zhitong Hong Kong Shareholders' Rights Disclosure | April 22
Disclosure of Hong Kong Stock Shareholders' Rights | April 22
China Biopharmaceuticals (01177.HK) received 2.5 million shares from Chairman Xie Qirun
Gelonghui, April 22丨According to the latest equity disclosure data of the Stock Exchange, on April 19, 2024, China Biopharmaceutical (01177.HK) was granted an increase of 2.5 million shares at an average price of HK$2.3223 per share on the market, involving approximately HK$5.8058 million. After the increase in holdings, Xie Qirun's latest shareholding was 4 million shares, and the shareholding ratio increased from 0.01% to 0.02%.
China Biopharmaceutical (01177.HK) spent HK$11.682 million to buy back 5 million shares on April 19
Gelonghui, April 19, 丨 China Biopharmaceutical (01177.HK) issued an announcement. On April 19, 2024, it spent HK$11.682 million to repurchase 5 million shares at a repurchase price of HK$2.32-2.34 per share.
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug
Sino Biopharmaceutical's (HKG:1177) key clinical research for the registration of Rovadicitinib has met its primary endpoint, a Thursday filing on the Hong Kong bourse stated. The pharmaceutical compa
China Biopharmaceutical (01177.HK): Key registration study on Class 1 innovative rovaxitinib tablets ROVADICITINIB (TQ05105) obtained positive results
Gelonghui, April 18 | China Biopharmaceutical (01177.HK) announced that the key registered clinical study of the Class 1 innovative drug Rovadicitinib (TQ05105), a class 1 innovative drug independently developed by the Group for the treatment of medium- and high-risk myelofibrosis (MF), has reached the main end. The Group has communicated with the Drug Evaluation Center (CDE) of the China National Drug Administration on the marketing application for TQ05105 tablets and obtained the CDE's approval to submit the marketing application for this product. The Group will submit a listing application for TQ05105 in the near future. TQ05105 is a group
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares
Sino Biopharmaceutical's (HKG:1177) employee benefit trust (EBT) has purchased 5 million of the firm's shares from the secondary market at about HK$2.459 apiece, according to a Wednesday filing with t
China Biopharmaceutical (01177.HK): Trustee buys 5 million shares under restricted share award scheme
Gelonghui, April 17, 丨 China Biopharmaceutical (01177.HK) issued an announcement. On April 17, 2024, the trustee purchased an additional 5 million shares from the market and held them in trust on behalf of the selected participants in accordance with the terms and conditions of the program rules.
Zhitong Hong Kong Stock Repurchase Statistics|April 17
Hong Kong Stock Repurchase Statistics|April 17
China Biopharmaceutical (01177) spent HK$12.7 million to buy back 5 million shares on April 16
China Biopharmaceutical (01177) announced that on April 16, 2024, the company spent HK$12.7 million...
[Broker Focus] Bank Securities first granted China Biopharmaceutical (01177) “Recommended” rating indicates that its innovative products have entered a period of performance harvesting
Jinwu Financial News | According to Bank Securities Research, in 2023, China Biopharmaceutical (01177) had total operating revenue of 26.376 billion yuan (-8.71% YoY, +0.7% YoY if Chia Dao Dao's revenue scale was excluded), and net profit to mother was 2.33 billion yuan (8.32% YoY). Since the launch of anlotinib, the core product of innovative drugs, in 2018, the company has established a comprehensive innovation and transformation strategy. Since then, the transformation has been accelerated through various methods. Currently, the company has a rich pipeline of innovative drugs, and its innovative business revenue continues to grow rapidly, successfully transforming from a pharmaceutical company with a focus on generic drugs to a first-tier innovative drug manufacturer. This line
China Biopharmaceutical (01177): Trustee buys an additional 5 million shares under the Restricted Share Award Program
China Biopharmaceutical (01177) issued an announcement. On April 15, 2024, the trustee made further purchases from the market...
China Galaxy Securities: Innovation and Transformation Accelerating the Harvest Period, First “Recommended” Rating for China Biopharmaceuticals (01177)
With the help of self-development+BD+ overseas platforms, China Biopharmaceutical (01177) has accelerated its innovation and transformation into a period of reaping performance.
No Data